Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: J Allergy Clin Immunol. 2021 Mar 10;147(6):2009–2020. doi: 10.1016/j.jaci.2021.02.037

TABLE III.

Complementary strengths and weaknesses of the 3 study arms of VAMPSS

Characteristic Strengths Potential weaknesses
Study design
Cohort • Prospective
• Multiple outcomes
• Limited statistical power for specific birth defects
• More costly
Case-control • Multiple exposures
• Statistical power for specific birth defects
• Less costly
• Retrospective
• Limited statistical power for infrequent exposures
Database • Prospective
• Population-based
• Multiple exposures
• Multiple outcomes
• Statistical power for groups of defects possible
• May be least costly
Medication exposure capture
Cohort • Data captured on medication as actually taken
• Data captured on OTC medications (including vitamins)
• Data captured on borrowed medication
Case-control • Data captured on medication as actually taken
• Data captured on OTC medications (including vitamins)
• Data captured on borrowed medication
• Retrospective exposure information
Database • Medication prescribed may not be taken
• Timing of exposure estimated when gestational age is not captured
Bias and confounding
Cohort • Outcomes confirmed by interview and medical records
• Data available on confounders, eg, alcohol, tobacco, and folic acid use
• Potential volunteer bias
Case-control • Outcomes confirmed by interview and medical records
• Data available on confounders, eg, alcohol, tobacco, and folic acid use
• Potential volunteer bias
• Potential recall bias
• Potential biased control selection
Database • No selection bias
• Diagnoses in pregnancy losses rarely captured
• Data not available for some key confounders, eg body mass index

OTC, Over-the-counter.